Pharmacokinetic Assessment of Sodium Sulfide in Subjects With Impaired Renal Function

Stopped early · Phase 1

Conditions studied: Renal Impairment

In brief

This is a Phase 1 study to assess the pharmacokinetics (PK) of IK-1001 (sodium sulfide) in healthy volunteers as well as in subjects with varying degrees of impaired renal function. A total of 28 subjects will be enrolled into the study over a 6 month period. There will be 4 cohorts. The first cohort will consist of subjects with mild renal impairment, the fourth cohort will be subjects with intermediate renal impairment and the third cohort will be subjects with severe renal impairment and the second cohort will consist of normal healthy subjects. All subjects will receive the study drug for 3 hours as a single intravenous (IV) infusion and will be followed over a 7 day period.

Key facts

Study ID

NCT00879645

Run by

Mallinckrodt

People needed

28

Starts

2009-08-01

Expected to finish

2010-03-01

Last updated by the study team

2019-12-17

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• For normal subjects arm (CrCL > 80 ml/min): Healthy male and female subjects age 18 to 70 years of age inclusive. Pregnant women are excluded and women of child-bearing potential must agree to the use of medically reliable contraceptive methods for the duration of the study and for 30 days after study.
• For renally impaired arm: Male and female - pregnant women are excluded and women of child-bearing potential must agree to the use of medically reliable contraceptive methods for the duration of the study and for 30 days after study. Subjects with mild, moderate and severe renal function aged between 18 to 70 years old
• Body mass index (BMI) within the range of 18 to 40 kg/m2
• Electrocardiogram (ECG) recording without clinically relevant abnormalities
• Having had no febrile or infectious disease for at least seven days prior to dosing of study drug
• Able to communicate well with the study staff and to understand and comply with the requirements of the study, understand and sign the written informed consent

You may not qualify if…

• High risk patients who may need an urgent dialysis during clinical conduct portion of the study (from Day -1 until last PK sampling on Day 7)
• All smokers.
• More than moderate alcohol consumption (>35 g ethanol regularly or > 2 drinks per day )
• Any history of alcohol or drug abuse
• Any active physical or psychiatric disease, acute or chronic
• Any clinically relevant history of drug hypersensitivity, asthma, urticaria or other severe allergic diathesis
• Pregnant or nursing women
• Blood donation within 30 days
• Participation in any clinical study within 30 days prior to the treatment phase of this study
• Lab values outside of reference range and clinically relevant liver function tests (AST, ALT, gamma-GT)
• Positive tests for HIV antibodies, Hepatitis B-virus surface antigen (HBsAg), Anti-Hepatitis C-virus antibodies (Anti-HCV)

Where it is running

• DaVita Clinical Research — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.